Open AccessPB2080: EFFICACY AND SAFETY OF BENDAMUSTINE‐BASED REGIMENS AS FIRST‐LINE TREATMENT FOR INDOLENT B‐CELL NON‐HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL‐WORLD STUDY IN CHINA
Author(s) -
Li S.,
Wen S.J.,
Ma J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851152.49123.64
Subject(s) - bendamustine , medicine , rituximab , clinical endpoint , neutropenia , oncology , tolerability , lymphoma , international prognostic index , chemotherapy , adverse effect , clinical trial